CALL/NOVO-NORDISK B/1500/0.1/20.12.24 | Real-time Bid/Ask 11:04:17 2024-06-11 am EDT | ||
| 0.1 EUR / 0.13 EUR | -4.17% |
|
| Current month | +50.00% | ||
| 1 month | +20.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-11 | 0.11 | -8.33% |
| 24-06-10 | 0.12 | +9.09% |
| 24-06-07 | 0.11 | -15.38% |
| 24-06-06 | 0.13 | +44.44% |
| 24-06-05 | 0.09 | +28.57% |
Delayed Quote Börse Stuttgart
Last update June 11, 2024 at 05:12 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GG4UHM |
| ISIN | DE000GG4UHM5 |
| Date issued | 2024-03-05 |
| Strike | 1,500 kr |
| Maturity | 2024-12-20 (192 Days) |
| Parity | 10 : 1 |
| Emission price | 0.08 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.25 € |
|---|---|
| Lowest since issue | 0.061 € |
| Spread | 0.03 € |
| Spread % | 23.08% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
988.4
DKK
Average target price
929.5
DKK
Spread / Average Target
-5.96%
- Stock Market
- Warrants
- Warrant
